Company Profile

Company Description:

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by 2012 prescription drug sales (after Pfizer, Sanofi, Novartis, Merck & Co., Roche and GlaxoSmithKline) and has operations in over 100 countries.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.^[5] The company was founded in 1999 through the merger of theSweden-based Astra AB and the UK-based Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including ofCambridge Antibody Technology (in 2006), MedImmune (in 2007), and Spirogen (in 2013).
AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had amarket capitalisation of approximately £54.8 billion as of 1 August 2014, the sixth largest of any company with a primary listing on the London Stock Exchange.^[8] It has secondary listings on the New York Stock Exchange and theOMX exchange.